Please login to the form below
cost
This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.
NHS wins legal fight with pharma over off-label Avastin
The cost implications are clear, as the court judgement showed: it says Avastin’s list price is around £28 per injection; Eylea around £816 per injection; Lucentis around £551 per injection. ... The case could not only open the door for more
Latest news
-
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness. ... NICE says costs associated with managing and treating adverse events should therefore be reflected in its cost-effectiveness modelling.
-
Innovate UK awards £1m for AI drug discovery project
Currently 90% of drugs fail somewhere between phase 1 trials to regulatory approval, which means pharmaceutical companies are often incurring high drug developmental costs, but this new initiative hopes to improve
-
Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... Just last week NICE issued
-
Teva wins FDA OK for crucial migraine drug
In a statement, Teva said that it had set a list price of $575 for the monthly dose and $1, 725 for the quarterly dose, giving an annual cost of $6, ... It is estimated that with discounts the annual cost of the drugs could be around the $5, 000 mark.
-
Controversy grows around GP at Hand service after minister’s endorsement
cost of basic, face-to-face, holistic care for patients who rely on their GP the most.
More from news
Approximately 10 fully matching, plus 1,184 partially matching documents found.
Latest Intelligence
-
Cannes Lions Healthcare Agency of the Year – championing change and demanding more…
In the UK the estimated cost of the NHS is £134bn and the estimated value provided by unpaid carers is £132bn, a difference of just 1.5%.
-
The European Medicines Agency: PRIME’d for access?
What may prove to be a stumbling block for patients getting access – and companies getting revenue – could well be cost.
-
The race for an HIV ‘cure’
Cost is not the issue. HIV research is swirling with new candidates, molecules and potent combination drugs in feverish competition for the market. ... Cost is not the issue; it’s the education and infrastructure that is needed to make sure the health
-
Brand teams: why are some smarter than others?
When one controls for the product differentiation created by R&D, not marketing, the added value created by many brand teams is often less than they cost.
-
Trust me, I’m from pharma
It provides a mechanism to contract around other types of outcomes such as pathway performance, cost-savings and humanistic or societal benefits.
More from intelligence
Approximately 2 fully matching, plus 396 partially matching documents found.
Latest appointments
-
Merck appoints new chief information officer
He has a proven track record in successfully managing large-scale IT transformation initiatives, as well as building cost-effective international IT organisations.”.
-
Baird Capital backs Prescient Healthcare Group
decisions. “The market for the company’s services is set to continue to grow strongly as biopharmaceutical companies seek to develop and market products in a cost- and time-effective way.
-
Peter Kelly named managing director of Accord Healthcare UK
We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Sandoz UK promotes Tim de Gavre to country head
As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs,
More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
More tell, less sell: HCP-centric comms
Furthermore, additional meals and meals of higher cost were associated with even higher relative prescribing rates.
-
Moving away from pharma’s paternalistic approach
spiralling R&D costs — will make co-creating medicines with patients crucial to pharma companies’ ability to continue to deliver patient value.
-
HSJ Awards Finalists Announced
The Partnership Awards celebrate the people and businesses promoting joint working and supplier innovation to deliver better and more cost-effective patient care.
-
Attracting and retaining talent – recruiting the workforce of the future
In fact, it may bring improved staff motivation, recruitment and retention, greater customer satisfaction, increased productivity, reduced sickness, and greater cost-effectiveness.".
-
Genetic counsellors: the new healthcare influencers?
The US government will cover the costs, signalling their commitment to more precise treatment that will drive better outcomes for patients across the U.S.
More from PMHub
Approximately 3 fully matching, plus 345 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Associate Scientific Director
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Account Director or Senior Account Director
-
Salary TBC
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Systematic Review Lead- London
-
Negotiable
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Account Manager
-
Negotiable
Subscribe to our email news alerts
- Moving annual total (MAT)
- Key success factor (KSF)
- AZ prepares to file COPD triple, taking on rival GSK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Gilead targets hep B in half a billion dollar deal with Precision BioSciences
- Teva wins FDA OK for crucial migraine drug
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
